| Revenue growth | Reported 2% Y-o-Y growth; adjusted for accounting change 4%. |
|---|---|
| Margins | Current EBITDA 16.7%; guided 18.5-20% for FY27. |
| Demand visibility | Strong traction in obesity and chronic segments. |
| Management confidence | High on U.S. pipeline and chronic therapy momentum. |
Growth
Revenue hit INR 7,119 Cr; One India grew 12% Y-o-Y; US sales at $162M; PAT at INR 789 Cr.
Outlook
EBITDA margin guidance maintained at 18.5%-20% for FY27; targeting $1 billion U.S. exit run-rate by year-end.
Risks
Loss of South African tenders; currency fluctuations; war-related costs impacting margins by 1-2%; inventory write-offs.
Last quarter's promises, checked
Delivered
- Launch generic Ventolin in coming months → Launched in Q1 FY27 (= BEAT)
- India double-digit growth → Delivered 12% Y-o-Y (= BEAT)
- US Albuterol share 19.5% to 20% → Maintained higher-than-proportionate share (= BEAT)
Partly delivered
- 4 US respiratory launches in FY27 → 1 launched, 3 pending (= PARTIAL)
- US $1B exit run-rate target → Current quarterly $162M ($648M annual) (= PARTIAL)
Missed
- EBITDA margin 18.5%-20% → Delivered 16.7% in Q1 (= MISS)
Earnings Call Transcript filed with BSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,333.00
- Market cap
- ₹1,07,689 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 31.9×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Partnership
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
Cipla Merger & Restructuring
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.